{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:58:25Z","timestamp":1789016305048,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015208","name":"Comprehensive Transplant Institute, University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016253","name":"Atara Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jtct.2022.06.019","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T09:27:22Z","timestamp":1656235642000},"page":"546-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.06.019_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.06.019_bib0004","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0005","article-title":"Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy","author":"Bachanova","year":"202040","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2022.06.019_bib0006","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.019_bib0007","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-020-0892-7","article-title":"CAR T-cell therapy for the management of refractory\/relapsed high-grade B-cell lymphoma: a practical overview","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0008","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0009","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0010","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.06.019_bib0011","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0012","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0013","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0014","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0015","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0016","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0017","doi-asserted-by":"crossref","first-page":"55.e1","DOI":"10.1016\/j.bbmt.2020.09.004","article-title":"Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy","volume":"27","author":"Bal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0018","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.32752","article-title":"Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation","volume":"126","author":"Jagadeesh","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.019_bib0019","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0020","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0021","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0022","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0024","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0026","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0027","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0028","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2022.06.019_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"suppl 4","key":"10.1016\/j.jtct.2022.06.019_bib0030","article-title":"How I treat adverse effects of CAR-T cell therapy","volume":"4","author":"Y\u00e1\u00f1ez","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtct.2022.06.019_bib0031","first-page":"581","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B-cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0032","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0033","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0034","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0035","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0036","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0037","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0038","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0039","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0040","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"Cuccuini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0042","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0043","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jtct.2021.02.005","article-title":"Predicting outcomes following anti-CD19 CAR T cell therapy in aggressive B cell lymphomas","volume":"27","author":"Ho","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0044","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0045","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0046","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0047","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","author":"Smith","year":"202228713","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0048","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/bloodadvances.2021004604","article-title":"Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers","volume":"5","author":"Paczesny","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0049","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/annonc\/mdw653","article-title":"Treatment outcomes for older patients with relapsed\/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial","volume":"28","author":"Davison","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0050","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0051","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.019_bib0052","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0053","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0054","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0055","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0056","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0057","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0058","article-title":"Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0059","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0060","doi-asserted-by":"crossref","unstructured":"Ahmed N, Kumar A, Kharfan-Dabaja MA, et al. ASTCT committee on practice guidelines survey on evaluation & management of diffuse large B-cell lymphoma after failure of chimeric antigen receptor T cell therapy (CAR-T) therapy [e-pub ahead of print]. Transplant Cell Ther. doi: 10.1016\/j.jtct.2022.05.043, accessed 6\/20\/2022","DOI":"10.1016\/j.jtct.2022.05.043"},{"key":"10.1016\/j.jtct.2022.06.019_bib0061","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11864-021-00906-4","article-title":"How to sequence therapies in diffuse large B-cell lymphoma post-CAR-T cell failure","volume":"22","author":"Logue","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0062","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0063","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0064","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies","volume":"11","author":"Cheson","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.06.019_bib0066","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0067","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0068","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0069","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0071","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0072","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0073","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0074","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjh.17460","article-title":"The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy","volume":"193","author":"Dholaria","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hon.2845","article-title":"Allogeneic stem cell transplant in non-Hodgkin lymphomas: still an indication?","volume":"39","author":"Dreger","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0076","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0077","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0078","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0079","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8012","article-title":"Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1","volume":"38","author":"Locke","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0081","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0082","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0083","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0084","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/HS9.0000000000000295","article-title":"The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy","volume":"3","author":"Lekakis","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2022.06.019_bib0085","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0086","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","article-title":"Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival","volume":"13","author":"Eapen","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0087","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0088","article-title":"Outcomes of aggressive B cell lymphoma patients with no evidence of measurable disease at the time of CD19 chimeric antigen receptor T cell therapy: the experience from the CAR T Cell Consortium","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0089","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/bmt.2015.246","article-title":"Geographic access to hematopoietic cell transplantation services in the United States","volume":"51","author":"Delamater","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0091","unstructured":"Moskop A, Hu ZH, Pasquini MC. Current uses of CAR T cell Therapies in the US: CIDR summary slides, 2020. Vol 20222020. https:\/\/www.cibmtr.org\/About\/WhatWeDo\/CIDR\/Pages\/default.aspx."},{"key":"10.1016\/j.jtct.2022.06.019_bib0092","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0093","article-title":"Enrollment of Black Americans in pivotal clinical trials supporting Food and Drug Administration (FDA) chimeric antigen receptor (CAR)-T cell therapy approval in hematological malignancies","volume":"138","author":"Al Hadidi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0094","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/v13081528","article-title":"Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives","volume":"13","author":"Labb\u00e9","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jtct.2022.06.019_bib0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bjid.2012.06.012","article-title":"Autologous transplant: microbial contamination of hematopoietic stem cell products","volume":"16","author":"Almeida","year":"2012","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jtct.2022.06.019_bib0096","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.transci.2016.05.001","volume":"55","author":"Dal","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtct.2022.06.019_bib0097","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1111\/trf.12150","article-title":"Microbial contamination of hematopoietic progenitor and other regenerative cells used in transplantation and regenerative medicine","volume":"53","author":"Jacobs","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2022.06.019_bib0098","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2019002258","article-title":"CAR T cell viability release testing and clinical outcomes: is there a lower limit?","volume":"134","author":"Chong","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0099","article-title":"Outcomes in aggressive B-cell non-Hodgkin lymphomas with anti-CD19 CAR T-cell (CTL019) products not meeting commercial release specifications","volume":"134","author":"Chong","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2022.06.019_bib0101","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.019_bib0102","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2022.06.019_bib0103","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"issue":"suppl","key":"10.1016\/j.jtct.2022.06.019_bib0104","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.bbmt.2018.12.112","article-title":"Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies","volume":"25","author":"Shah","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl","key":"10.1016\/j.jtct.2022.06.019_bib0105","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.bbmt.2019.12.114","article-title":"Resource utilization and factors prolonging hospitalization for patients with refractory and relapsed B-cell lymphoma receiving axicabtagene ciloleucel (Axi-cel)","volume":"26","author":"Mian","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.06.019_bib0106","article-title":"Estimation of the resource utilization and costs of cytokine release syndrome observed in the Transcend-NHL clinical trial: a micro-costing study","volume":"132","author":"Siddiqi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.019_bib0107","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2022.06.019_bib0108","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0109","doi-asserted-by":"crossref","first-page":"506.e1","DOI":"10.1016\/j.jtct.2021.03.005","article-title":"Cost effectiveness analysis of tisagenlecleucel for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma in Japan","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtct.2022.06.019_bib0111","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.06.019_bib0112","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.019_bib0113","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0114","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S2666-6367(22)00782-5","article-title":"LBA2 - cost-effectiveness of axicabtagene ciloleucel as second-line therapy for patients large B-cell lymphoma (LBCL) in the United States","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0115","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1016\/S2666-6367(22)00587-5","article-title":"Cost-effectiveness of CD19 chimeric antigen receptor t cell therapy versus autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in first relapse","volume":"28","author":"Kelkar","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.019_bib0116","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: building on the CD19 paradigm","volume":"51","author":"Globerson Levin","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0117","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.06.019_bib0118","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11864-021-00920-6","article-title":"Allogeneic chimeric antigen receptor therapy in lymphoma","volume":"23","author":"Khurana","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtct.2022.06.019_bib0119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC-Derived natural killer cell therapies - expansion and targeting","volume":"13","author":"Goldenson","year":"2022","journal-title":"Front Immunol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:06:13Z","timestamp":1763003173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722014117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":119,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666636722014117"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}